Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients
Article 2023 en
Authors
NA
Nicholas Allen
AM
Andrew Martin
VS
Victoria A. Snaidr
Abstract
1 min read
In this 12-month, placebo-controlled trial, oral nicotinamide therapy did not lead to lower numbers of keratinocyte cancers or actinic keratoses in immunosuppressed solid-organ transplant recipients. (Funded by the National Health and Medical Research Council; ONTRANS Australian New Zealand Clinical Trials Registry number, ACTRN12617000599370.).
Andrew C. Chen, Andrew Martin, Bonita Choy, Pablo Fernández‐Peñas, Robyn A. Dalziell, Catriona McKenzie, Richard A Scolyer, Haryana M. Dhillon, Janette L. Vardy, Anne Kricker, Gayathri St George, Niranthari Chinniah, Gary M. Halliday, Diona L. Damian
Andrew Martin, Andrew Chen, Bonita Choy, Pablo Fernández‐Peñas, Gary M. Halliday, Robyn A. Dalziell, Catriona McKenzie, Richard A Scolyer, Haryana M. Dhillon, Janette L. Vardy, Gaya St George, Nira Chinniah, Diona L. Damian
Luigi Naldi, Anna Belloni Fortina, Silvia Lovati, Annalisa Barba, Eliana Gotti, Gianpaolo Tessari, Donatella Schena, Andrea Diociaiuti, G Nanni, Ilaria Lesnoni La Parola, Cinzia Masini, Stefano Piaserico, Andrea Peserico, T. Cainelli, Giuseppe Remuzzi
Discussion(0)
No comments yet. Be the first to comment.